A Phase II Study of VNP40101M [laromustine] For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia.

Trial Profile

A Phase II Study of VNP40101M [laromustine] For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs Laromustine (Primary) ; Hydroxycarbamide
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Additional trial centre identified, additional trial identifier 2004-0140 identified as reported by M.D. Anderson Cancer Center record.
    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top